Among the strengths of the present prospective study are the use of a clinical database for registration of PSA test rates and the classification of PSA into incident tests, repeated normal tests, and repeated raised tests.13 Furthermore, from the Danish CRN, it was possible to exclude male patients who had been diagnosed with prostate cancer and are monitored with regular PSA tests. This evidence concerns the gene KLK3 and Familial prostate cancer.